covid-19 outbreak vaccine Coronavirus

Adagio Therapeutics launches with focus on coronavirus antibodies

Reading now: 954
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Biotechnology startup Adagio Therapeutics, a spin-out of Adimab, has launched with $50m in Series A funding to support its work on coronavirus antibodies that could prevent and treat Covid-19, as well as any future coronavirus outbreaks.

Multiple companies, including Johnson & Johnson and Moderna, are developing potential vaccines against the disease. Adagio Therapeutics engineered antibody candidates to neutralise and protect against SARS-CoV-2, SARS-CoV-1 and other circulating bat coronaviruses.

The company expects these monoclonal antibodies to deliver potency and coverage against SARS-CoV-2, which causes Covid-19, as well.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA